GlassScriptPhysician profile
Jia Hao Liang
NPI 1629503222
$2,101.43
in general payments reported to CMS, 2019-2025
38 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $111 · 2024: $685 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,990.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $262.26 | 2024-2025 | |
| Pfizer INC. | $136.35 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $115.09 | 2022-2024 | Xarelto |
| Abbvie INC. | $110.11 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $95.94 | 2024-2025 | Imfinzi, Enhertu |
| Array Biopharma INC | $89.60 | 2025 | Braftovi, Lorbrena, Mektovi |
| Astellas Pharma US INC | $88.52 | 2024-2025 | Xtandi, Padcev, Xospata |
| Incyte Corporation | $80.90 | 2025 | Jakafi, Niktimvo |
| Sobi, INC | $72.31 | 2024 | |
| Servier Pharmaceuticals LLC | $71.88 | 2024-2025 | |
| Genzyme Corporation | $65.42 | 2025 | |
| Jazz Pharmaceuticals INC. | $65.08 | 2024-2025 | |
| Janssen Biotech, INC. | $64.06 | 2024 | Erleada, Balversa, Akeega |
| Adaptive Biotechnologies Corporation | $57.84 | 2024-2025 | Clonoseq |
| Merck Sharp & Dohme LLC | $54.00 | 2024-2025 | Keytruda, Welireg |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $51.68 | 2024-2025 | Ninlaro |
| Ipsen Biopharmaceuticals, INC | $44.15 | 2024-2025 | Onivyde |
| Glaxosmithkline, LLC. | $43.50 | 2025 | Ojjaara, Jemperli, Zejula |
| Genmab U.S., INC. | $40.48 | 2024 | Epkinly |
| E.R. Squibb & Sons, L.L.C. | $40.36 | 2022-2025 | Opdivo |
| Alexion Pharmaceuticals, INC. | $40.19 | 2024-2025 | Ultomiris |
| Tersera Therapeutics LLC | $39.68 | 2025 | Xermelo |
| Novocure INC. | $28.85 | 2024 | Optune Lua (Novottf-200t) |
| Amneal Pharmaceuticals LLC | $28.79 | 2024 | Avastin |
| Azurity Pharmaceuticals, INC. | $27.55 | 2025 | Danziten |
| Celltrion USA INC. | $26.08 | 2025 | Vegzelma |
| Genentech USA, INC. | $25.51 | 2024 | Polivy, Columvi, Lunsumio |
| Regeneron Healthcare Solutions, INC. | $25.44 | 2025 | Libtayo |
| Beone Medicines USA, INC. | $25.14 | 2025 | Brukinsa |
| Lilly USA, LLC | $24.72 | 2025 | Jaypirca, Verzenio |
| Acrotech Biopharma INC. | $22.93 | 2025 | Beleodaq |
| Kite Pharma, INC. | $21.60 | 2024 | Yescarta |
| Aveo Pharmaceuticals, INC. | $21.45 | 2025 | |
| Apellis Pharmaceuticals, INC. | $21.20 | 2025 | Empaveli |
| Avyxa Pharma, LLC | $21.06 | 2025 | |
| Alnylam Pharmaceuticals INC. | $20.67 | 2025 | Givlaari |
| Cumberland Pharmaceuticals, INC. | $17.20 | 2024 | Sancuso |
| Recordati_rare_diseases_inc. | $13.84 | 2025 | Enjaymo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jia Hao Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.